Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 383, Issue 19, Pages 1813-1826Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa2007764
Keywords
-
Categories
Funding
- NIAID, National Institutes of Health (NIH), Bethesda, MD
- NIAID, NIH [HHSN261200800001E 75N910D00024, 75N91019F00130/75N91020F00010]
- National Cancer Institute, NIH [HHSN261200800001E 75N910D00024, 75N91019F00130/75N91020F00010]
- Department of Defense, Defense Health Program
- NIAID of the NIH [UM1AI148684, UM1AI148576, UM1AI148573, UM1AI148575, UM1AI148452, UM1AI148685, UM1AI148450, UM1AI148689]
- Seoul National University Hospital
- United Kingdom Medical Research Council [MRC _UU_12023/23]
- Sanofi Pasteur
- Gilead
- Gilead Sciences
- Merck Sharp and Dohme
- ViiV Healthcare
- Gilead Sciences Europe
- Pfizer
- Novo Nordisk Foundation
- Simonsen Foundation
- Lundbeck Foundation
- GlaxoSmithKline
- Janssen
- government of Denmark
- government of Japan
- government of Mexico
- government of Singapore
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000936, ZIAAI000984] Funding Source: NIH RePORTER
- MRC [MC_UU_12023/22] Funding Source: UKRI
Ask authors/readers for more resources
BackgroundAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. MethodsWe conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. ResultsA total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). ConclusionsOur data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.) In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 days, vs. 15 days with placebo). The estimates of mortality by day 29 were 11.4% with remdesivir and 15.2% with placebo. The benefit of remdesivir was most apparent in patients who were receiving low-flow oxygen at baseline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available